Gen­mab to ap­peal Darza­lex ar­bi­tra­tion against J&J

Gen­mab is plan­ning to file an ap­peal less than a week af­ter los­ing an ar­bi­tra­tion against John­son & John­son again over their li­cens­ing pact for the block­buster an­ti­body Darza­lex.

The case traces back to 2020, when J&J’s Janssen be­gan re­duc­ing its roy­al­ty pay­ments to Gen­mab for Darza­lex, prompt­ing the biotech to seek le­gal clar­i­fi­ca­tion on the ex­act amount it’s owed.

Pri­or to that, Janssen struck a deal with Halozyme to de­vel­op a sub­cu­ta­neous ver­sion of the drug, now sold as Darza­lex Faspro in the US, and the com­pa­ny ar­gued that Gen­mab was re­quired to share in its roy­al­ty pay­ments to Halozyme. As a re­sult, Janssen be­gan re­duc­ing its roy­al­ty pay­ments to Gen­mab to off­set the costs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER